Xinsorb® Bioresorbable Sirolimus-eluting Scaffold

Completely degradable and resorbable

Xinsorb® Bioresorbable Sirolimus-eluting Scaffold



Product Advantages

  • The final degradation products of the stent are water and carbon dioxide, reducing the risk of late thrombosis.
  • Easy to re-stent even after target lesion restenosis.
  • Completely degradable and resorbable, reducing the risk of foreign body reaction.
  • Help to restore and improve the physiological function of the diseased vessels.
  • Compatible with MRI & CT


  • Patients with myocardial ischemia or angina pectoris caused by coronary artery stenosis or occlusion.
  • Patients with primary or in-situ coronary thrombosis.
  • The diameter of the diseased vessel is between 2.75mm-3.75mm, and the length of the diseased vessel is ≤24mm
  • Patients with probable severe acute occlusion complications after PTCA.
  • Patients with obvious residual stenosis in the lesion after PTCA.

First-in-man experience of XINSORB® Bioresorbable Sirolimus-eluting Scaffold

35-year-old man with type II diabetes and subacute myocardial infarction.

5th Sep. 2013


After the surgery (3.0*18mm XINSORB®)

6 months and 2 years after the surgery
6 months and 2 years after the surgery
6 months and 2 years after the surgery
Clinical data: The comparison of single-group target value test evaluation indicators results in 2 years
Analysis of 3-year clinical follow-up data
Analysis of 3-year clinical follow-up data


  • The XINSORB® Bioresorbable Sirolimus-eluting Scaffold (hereinafter referred to as XINSORB® Scaffold System) is composed of a balloon-expandable absorbable coronary stent, a drug coating and a delivery system. As shown in the figure.

Major structures

  • Balloon-expandable absorbable polymer stent
  • Drug coating
  • Delivery system

The structure of XINSORB® Scaffold System

XINSORB® Scaffold specifications

Length Diameter
12mm 15mm 18mm 23mm 28mm
Φ 2.75mm
Φ 3.00mm
Φ 3.50mm